and a cause-and-effect relation must be viewed with great caution. Certainly, autopsy examination could shed light in some instances but may not be conclusive in others. Many other experiences suggest that progressive myocardial failure dominates this component of mortality. A concomitant increase in the frequency of ICD discharges and earlier device activation can accompany this deterioration.14"6 Critical examination of the nature of nonsudden cardiac death will be valuable in A secondary theme in this report is the potentially limited benefit derived by patients with left ventricular ejection fractions of less than 30% with ICD therapy. Quantitation of survival benefit in prospective clinical trials has established a firm scientific rationale for the use of widely applied treatments. A much less complete data base exists for ICD therapy. Projected survival rates, even with their attendant limitations, suggest a dismal outcome for these VT/VF patients without ICD intervention.9'10 One-year projected survival rates range from 36% to 56%, and one report projected a 6% survival at 3 years. Although more frequent device use has been reported in patients with depressed left ventricular function, in our experience, the incidence of ICD use stratified by left ventricular ejection fraction (<30% and >30%) has been comparable after 4 years of follow-up. Cardiac survival for patients with low ejection fractions (.30%) has been comparable in ICD users and nonusers. This again suggests that the expected negative impact of VT/VF recurrences is avoided by the use of ICD therapy. Finally, measurement of ICD benefit has been until now largely focused on survival data. Another benefit yet to be quantified is the avoidance of prolonged hospitalization, which accompanies recurrences of sustained VT/VF in this population. Prompt arrhythmia reversion by the ICD obviates this clinical and economic burden and merits study. The opportunity to avoid hospitalization may be most valuable to patients, such as those in this report, with limited survival expectations. Clearly, rational minimum limits to life expectancy also must be defined before the institution of ICD therapy. Existing data from cardiac transplant candidates may provide important insights in this issue. 18 How can and should the issues raised be objectively addressed? The problem and its multiple facets argue for a controlled randomized clinical trial comparing ICD therapy with the best alternative therapy available for the largest proportion of VT/VF patients. Analogous to all other cardiovascular therapies, the primary end point of such a trial must be total mortality or total cardiovascular mortality. Secondary end points, such as the incidence of sudden death and VT/VF recurrences, should be examined. Prospective definitions of end points consistent with other antiarrhythmic trials should be considered. '9'20 An intention-to-treat analysis from the point of selection of ICD or alternative therapy is essential. Comparison with medically treated patients in reported clinical studies as discussed by Kim et a17 is fraught with a variety of perils that will be obviated by using the treatment-intent approach. For example, the medical in-hospital mortality of drug therapy selection empirically or otherwise is rarely available. In one report from our center, during in-hospital establishment of amiodarone therapy, recurrences occurred with a frequency up to 61% with a small but definite in-hospital mortality. 21 
